Ascendis Pharma A/S (NASDAQ:ASND) Lowered to “Sell” at StockNews.com

StockNews.com cut shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a sell rating in a research report sent to investors on Wednesday.

Several other research firms have also issued reports on ASND. Wedbush reaffirmed an outperform rating and issued a $192.00 target price on shares of Ascendis Pharma A/S in a report on Wednesday. HC Wainwright reiterated a buy rating on shares of Ascendis Pharma A/S in a research note on Monday, October 9th. Morgan Stanley upped their price objective on Ascendis Pharma A/S from $109.00 to $113.00 and gave the company an equal weight rating in a research note on Wednesday, September 6th. Bank of America upped their price objective on Ascendis Pharma A/S from $107.00 to $113.00 in a research note on Thursday, September 7th. Finally, Cantor Fitzgerald reiterated an overweight rating and issued a $152.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, September 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $141.00.

Ascendis Pharma A/S Stock Performance

ASND stock opened at $94.74 on Wednesday. The firm has a market cap of $5.46 billion, a PE ratio of -8.38 and a beta of 0.48. The company has a quick ratio of 2.65, a current ratio of 3.52 and a debt-to-equity ratio of 7.39. The business has a 50 day moving average of $94.27 and a 200-day moving average of $91.65. Ascendis Pharma A/S has a 12-month low of $64.33 and a 12-month high of $134.52.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 5th. The biotechnology company reported ($2.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.68) by $0.33. The company had revenue of $51.59 million during the quarter, compared to analyst estimates of $41.73 million. Ascendis Pharma A/S had a negative return on equity of 257.83% and a negative net margin of 500.93%. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -9.66 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors have recently made changes to their positions in the stock. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its position in shares of Ascendis Pharma A/S by 9.4% during the second quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 6,363 shares of the biotechnology company’s stock worth $568,000 after acquiring an additional 547 shares in the last quarter. AE Wealth Management LLC purchased a new stake in shares of Ascendis Pharma A/S in the second quarter worth $529,000. Candriam S.C.A. raised its position in shares of Ascendis Pharma A/S by 31.5% in the first quarter. Candriam S.C.A. now owns 250,375 shares of the biotechnology company’s stock worth $24,709,000 after buying an additional 60,000 shares in the last quarter. Alpha DNA Investment Management LLC purchased a new stake in shares of Ascendis Pharma A/S in the second quarter worth $768,000. Finally, Parkwood LLC raised its position in shares of Ascendis Pharma A/S by 6.4% in the first quarter. Parkwood LLC now owns 18,678 shares of the biotechnology company’s stock worth $2,003,000 after buying an additional 1,125 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia.